Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
November 21 Product: Jazz and Zymeworks Ziihera Indication: HER2-positive biliary tract cancer With the FDAs approval of Ziihera on Thursday, Jazz Pharmaceuticals and Zymeworks will go toe-to-toe with AstraZeneca and Daiichi Sankyo, whose antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan-nxki) was given a broad tumor-agnostic approval in April 2024
It also interacts with certain medications, including some thyroid drugs and blood thinners
This pattern is normal and expectedmost patients report that nausea becomes minimal or absent by their second or third month once they reach their effective therapeutic dose
This prevents the crashes associated with traditional diets
